Search 

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Humabs BioMed is a profitable Swiss biotech company that is discovering and developing nature-selected human monoclonal antibodies using proprietary platforms. 

Humabs is currently focusing on the development of human antibodies to fight infectious diseases. Additional indications are being targeted at the discovery research stage.

Humabs has already achieved four major licensing deals with Pharmaceutical companies generating significant revenues in the form of near term revenues, as well as a stream of longer term milestones and royalties. Two of these programs are in clinical development phases.

Humabs is seeking additional investments to allow the company to bring selected programs into clinical research on its own, thus significantly increasing the added value.

Immunimed Inc is a clinical-stage Biopharmaceutical company developing innovative egg-derived, oral potclonal antibody therapy to treat gastro-enteric infections/diseases. Our lead product IMM-001 targets super bug, Clostridium difficile, leading cause of hospital-acquired infections.

Currently is Phase II ready with remarkable clinical response in Proof on Concept multi-center clinical studies.  Phase II clinical study is planned for Q2 2015.

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Our technology instructs a patient's cells to constantly secrete gene-encoded medicines (biologics). It will enable new treatments by solving current delivery limitations and production challenges. We are initially targeting orphaned diseases. 

Immusoft’s platform can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. This approach makes possible treatments that are otherwise impractical due to short halflife, injection site reactions, production challenges or a small market size. It offers many of the benefits of traditional approaches and modern gene therapies with less risk and greater control.

Immusoft has received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. We have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

ISP technology could replace a lifetime of infusions with a patient’s own drug-producing cells.